References
- Visani G1, Malerba L, Maria Stefani P, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;22:3419–3425.
- Redondo AM, Valcárcel D, González-Rodríguez A, et al. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. 2019;184:797–807.
- Chantepie SP, Garciaz S, Tchernonog E, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma study association (LYSA) centers. Am J Hematol. 2018;93(6):729–735. doi:10.1002/ajh.25077
- Lachance S, Bourguignon A, Boisjol JA, et al. Impact of implementing a bendamustine-based conditioning regimen on outcomes of autologous stem cell transplantation in lymphoma while novel cellular therapies emerge. Transplant Cell Ther. 2023;29(1):34.e1–34.e7. doi:10.1016/j.jtct.2022.10.003
- Frankiewicz A, Saduś-Wojciechowska M, Najda J, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol (Pozn). 2018;22(2):113–117. doi:10.5114/wo.2018.77046
- Garciaz S, Coso D, Schiano de Collela J-M, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant. 2016;51(2):319–321. doi:10.1038/bmt.2015.257
- Lucijanic M, Prka Z, Jaksic O, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality. Am J Hematol. 2019;94(2):E42–E43. doi:10.1002/ajh.25340
- AlJohani NI, Nasani M, Ahmed HE, et al. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Oncol Stem Cell Ther. 2021;14(4):327–335. 121111 doi:10.1016/j.hemonc.2020.11.003
- Hueso T, Gastinne T, Garciaz S, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from lymphoma study association (LYSA) centers. Bone Marrow Transplant. 2020;55(6):1076–1084. doi:10.1038/s41409-020-0783-y